Faculty, Staff and Student Publications

Authors

    Language

    English

    Publication Date

    9-2-2025

    Journal

    Microbiology Spectrum

    DOI

    10.1128/spectrum.00798-25

    PMID

    40767523

    PMCID

    PMC12403768

    PubMedCentral® Posted Date

    8-6-2025

    PubMedCentral® Full Text Version

    Post-print

    Abstract

    Oral candidiasis (OC) is caused by Candida albicans, targeting immunocompromised individuals and developing drug resistance, highlighting the need for advanced therapeutics. Polyphenols such as caffeic acid phenethyl ester (CAPE) and ellagic acid (EA) display antifungal and immune-modulating properties. Incorporating CAPE and EA in gellan gum (GG) formulation enhances their applicability and effectiveness against OC. We developed GG-based formulations loaded with CAPE (1,000 µg/mL), EA (1,000 µg/mL), or CAPE + EA (1,000 µg/mL each) against C. albicans. GG formulations containing gellan (0.6% and 1.0%), genipin (5 mM), polyethylene glycol 400 (0.5%), and sorbitan monooleate 80 (0.5%) demonstrated enhanced release of CAPE and EA. The 0.6% GG formulation reduced C. albicans CFU by 2–6 log10 within 30 min (P < 0.05) and biofilm mass by 48% (CAPE, P = 0.0034), 60.7% (EA, P = 0.0980), and 70% (CAPE + EA, P = 0.0181). Both 0.6% and 1.0% GG formulations inhibited hyphae (P < 0.0001). GG formulations showed high viability of human red blood cells (92%–94%) and human gingival cells (61%–69%). In artificial chewing simulations (ACS), 0.6% GG exhibited 67.7% (30 min), 55.9% (60 min), and 35.8% (120 min) for CAPE release, and 48.2% (30 min), 45.1% (60 min), and 42.1% (120 min) for EA. In 1% GG, about 44.07% (30 min), 43.8% (60 min), and 29.5% (120 min) of CAPE and 55.8% (30 min), 49.6% (60 min), and 50.6% (120 min) of EA were released. The present study is the first to evaluate the efficacy of CAPE- and EA-loaded GG formulations against C. albicans under ACS, thereby supporting their potential development for OC treatment.

    Keywords

    Candidiasis, Oral, Candida albicans, Antifungal Agents, Humans, Biofilms, Polysaccharides, Bacterial, Polyphenols, Microbial Sensitivity Tests

    Published Open-Access

    yes

    Included in

    Dentistry Commons

    Share

    COinS
     
     

    To view the content in your browser, please download Adobe Reader or, alternately,
    you may Download the file to your hard drive.

    NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.